(Q35565167)

8 August 2017

1 reference

title

Risks associated with the use of intravenous immunoglobulin (English)

1 reference

8 August 2017

L Ross Pierce

1

1 reference

8 August 2017

Nisha Jain

series ordinal

2

1 reference

8 August 2017

language of work or name

1 reference

1 October 2003

1 reference

Transfusion Medicine Reviews

8 August 2017

published in

1 reference

8 August 2017

volume

17

1 reference

8 August 2017

issue

4

1 reference

8 August 2017

page(s)

241-251

1 reference

Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems

8 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

The reporting sensitivities of two passive surveillance systems for vaccine adverse events

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

Acute renal failure and intravenous immune globulin: sucrose nephropathy in disguise?

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

Acute renal failure resulting from intravenous immunoglobulin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

Recent developments in toxic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

Uveitis after antineutrophil cytoplasmic antibody contamination of immunoglobulin replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

Management of sickle cell disease. Acute chest syndrome is common in children before puberty

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

Aseptic meningitis following administration of intravenous immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

Recurrent aseptic meningitis complicating intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

Complications of intravenous gammaglobulin in neuromuscular and other diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

Intravenous immunoglobulin-induced lichenoid dermatitis: a unique adverse reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

Eczematous reactions to human immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

Severe, refractory epidermolysis bullosa acquisita complicated by an oesophageal stricture responding to intravenous immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

Meningitis and skin reaction after intravenous immune globulin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

Pompholyx (vesicular eczema) after i.v. immunoglobulin therapy for neurologic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

Neutropenia as a complication of intravenous immunoglobulin (IVIG) therapy in children with immune thrombocytopenic purpura: common and non-alarming

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

Complications of intravenous immune globulin treatment in neurologic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

Neutropenia in a patient receiving intravenous immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

Hemolysis following intravenous immune globulin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

Effect of high-dose intravenous immunoglobulin therapy on blood rheology

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

In vivo administration of intravenous immunoglobulin (IVIg) can lead to enhanced erythrocyte sequestration.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

Hemolytic anemia associated with intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

[A rare cause of intra-alveolar hemorrhage: a transfusion-related incident with leukoagglutination due to antigranulocyte antibodies (Trali syndrome)]

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

Hepatitis C transmission associated with intravenous immunoglobulins.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

Detection and characterization of hepatitis C virus RNA in immune globulins

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

Safety of intravenous immunoglobulin with regard to hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2803%2900038-5

7 January 2021

10.1016/S0887-7963(03)00038-5

Identifiers

DOI

1 reference

8 August 2017

1 reference